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Abstract 
Background: Human papilloma virus (HPV) vaccination in Nigeria will require substantial financing due to high 
cost of HPV vaccine and inexistence of structures to support adolescent vaccination. Alternative sources are needed 
to sustain the government funded HPV vaccination programme. This study assessed Nigerian mothers’ willingness-
to-pay (WTP) for HPV vaccine. We also compared the difference between the average WTP and estimated costs of 
vaccinating a pre-adolescent girl (CVG).
Methods: We conducted a quantitative, cross-sectional, survey-based study in which 50 questionnaires were 
distributed to each of 10 secondary schools located in two rural and one urban city in Anambra state. The question-
naires were then randomly distributed to girls aged 9–12 years of age to give to their mothers. Contingent valuation 
approach using the payment card technique was used to estimate the average maximum WTP among the survey 
participants. Correlates of WTP for HPV vaccination were obtained using multivariate logistic regression. Estimated 
CVG was obtained by adapting cost of HPV vaccine delivery in Tanzania to the Nigerian setting.
Results: A total of 438 questionnaires (88 %) were returned. The average WTP was US$ 11.68. This is opposed to esti-
mated delivery cost of US$ 18.16 and US$ 19.26 for urban and rural populations respectively at vaccine price offered 
by the Vaccine Alliance (Gavi) and US$ 35.16 and US$ 36.26 for urban and rural populations respectively at the lowest 
obtainable public sector vaccine price. Demand for HPV vaccine was deemed high (91.6 %) and was significantly asso-
ciated with respondents previously diagnosed of HPV infection.
Conclusion: Demand for HPV vaccine was high although short of estimated CVG. High demand for vaccine should 
be capitalized upon to increase vaccine uptake. Education on cervical cancer and provider-initiated vaccination 
should be promoted to increase vaccine uptake. Co-payment could be a feasible financing strategy in the event of 
national HPV vaccination.
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Background
Cervical cancer is the fourth most commonly diagnosed 
cancer and fourth leading cause of cancer related deaths 
among females worldwide [1]. Every year, about 528,000 
women around the world are diagnosed with cervical 
cancer and about 266,000 women die from the disease 
[1]. Cervical cancer ranks as the second most frequent 
cancer among women in Nigeria, with about 47 million 
women aged 15 years and older being reported to be at 
risk of developing cervical cancer. Further, almost 14,089 
Nigerian women are diagnosed with cervical cancer and 
8240 die from the disease yearly [2]. The health and eco-
nomic burden of cervical cancer is hence substantial. 
Cervical cancer deaths often occur in relatively young 
women, who are raising children, caring for families, and 
contributing to communities [3].
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While cervical cancer screening programmes have 
been effective in reducing cervical cancer incidence in 
developed countries, cervical cancer screening in Nige-
ria is still unpopular [2]. There is currently no organ-
ized national screening programme in the country. HPV 
screening is largely opportunistic, with screening cover-
age estimated to be around 8.7  % [2]. The two types of 
vaccines that prevent cervical cancer—GSK’s bivalent 
HPV vaccine (Cervarix) and Merck & Co. Inc.’s quad-
rivalent HPV vaccine (Gardasil)—are both licensed in 
Nigeria. The vaccines are highly effective in preventing 
persistent HPV infection and subsequent precancerous 
lesions due to infection with two types of HPV—types 16 
and 18—that cause about 70 % of cervical cancer world-
wide [2].
High prices have been a major barrier to introducing 
HPV vaccines in developing countries. The Vaccine Alli-
ance (Gavi) and its partners provide the poorest countries 
with access to a sustainable supply of new and underused 
vaccines. Gavi offers access to HPV vaccines for as lit-
tle as US$ 4.50 per dose and provides support for HPV 
demonstration programmes and the national introduc-
tion of HPV vaccines [4]. The type of support provided 
however depends on a country’s demonstrated ability to 
deliver vaccines to young adolescent girls [4]. Gavi’s cur-
rent vaccine support for Nigeria includes pentavalent, 
pneumococcal conjugate, yellow fever, meningitis A and 
measles vaccines, as well as cash support for health sys-
tem strengthening and immunization system strengthen-
ing [5].
Currently, HPV vaccines are purchased ‘out-of-pocket’ 
and are not included among the vaccines offered for free 
under the National Immunization Programme (NIP) in 
Nigeria. Providing free HPV vaccination would further 
strain the government’s tight health budget. Beside the 
cost of the vaccine, HPV vaccination requires the devel-
opment of a new vaccine delivery service for adolescent 
girls in order to achieve the required doses [6]. This is 
particularly due to the lack of an existing structure to 
support the adolescent vaccine delivery. Therefore, even 
with Gavi’s support, HPV vaccination will require a sub-
stantial sum of money for its delivery.
The National Primary Health Care Development 
Agency (NPHCDA) in Nigeria recently announced the 
commencement of plans for national HPV vaccina-
tion. The plan involves a demonstration project in some 
selected states of the federation in order to determine 
cost, acceptance and best delivery method [7]. A finan-
cially sustainable HPV vaccine delivery strategy is likely 
to require user financing to offset some percentage of the 
actual cost of vaccination. However, the viability of user 
fees as a financing mechanism for HPV vaccine depends 
on private demand for the vaccines. Several studies that 
assessed parental acceptance of HPV vaccination for 
their daughters in Nigeria reported high levels of accept-
ance for the vaccine [8–10]. However, to the best of our 
knowledge, no study has estimated the amount parents 
are willing to pay for the HPV vaccine. The objective of 
this study was to assess Nigerian mothers’ willingness-to-
pay (WTP) for the HPV vaccine using a contingent valu-
ation method. We also compared the difference between 
the average WTP value and estimated cost of vaccinat-
ing a pre-adolescent girl (CVG) against HPV infection in 
Nigeria. We focused on mothers because the responsibil-
ity of family health in many families mainly falls to the 
mother [11].
Methods
Study design and study population
This study, a school-based cross sectional survey was 
conducted in Anambra state, Nigeria, from February 
to August, 2015. Anambra state was selected due to its 
accessibility and proximity to the researchers. The state 
is located at latitude 6.20°N and 7.00°E with total area 
of 4844 km and population of 4.1 million [12]. The main 
indigenous ethnic group in Anambra state is Ibo and 
there is also a small population of Igala. The state con-
tains numerous thickly populated villages and small 
towns. Anambra state is rich in natural gas, crude oil, and 
bauxite and ceramic and has almost 100  % arable soil. 
Literacy level in the state is quite high. The inhabitants 
are mainly business people, government workers and 
students. According to the State Ministry of Education 
record, there are 254 public secondary schools and 166 
private secondary schools in the state.
Ten secondary schools (five schools in Onitsha, three 
schools in Ekwulobia and two secondary schools in Isuo-
fia) all in Anambra state were purposively selected for the 
study. Onitsha is an urban city while Ekwulobia and Isuo-
fia are rural cities. Five schools were privately owned while 
the other five were public schools. The reason for select-
ing schools from both urban and rural area as well as from 
both private and public schools was to ensure inclusion of 
persons from all socioeconomic strata. Eligibility for par-
ticipation (i.e. to be given a questionnaire) was (1) female 
students aged between 9 and 12  years old and (2) their 
mothers being able to read and write in English language.
Using Anambra state population size of 4.1 million 
[12], confidence level of 95 % and margin of error of 3 %, 
385 respondents (approximately 40 respondents/school) 
were determined to be appropriate for the survey. Fifty 
questionnaires were distributed to each of the 10 second-
ary schools to be distributed randomly to eligible girls.
The questionnaires were given to school teachers who 
distributed them to girls aged 9–12  years to take home 
to their mothers. The mothers were requested to return 
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the completed questionnaire via their child back to the 
school teachers within 3–7  days. Contingent valuation 
approach using the payment card technique was used to 
estimate the average maximum WTP among the survey 
participants.
Willingness‑to‑pay for HPV vaccine assessment
A 23-item self administered questionnaire was developed 
for the WTP assessment. The questionnaire consisted of 
three sections. The first section included general informa-
tion and socio-demographic characteristics such as age, 
number of daughters, level of education etc. The second 
section assessed awareness of HPV, genital warts, cervical 
cancer as well as HPV vaccines. Five questions examining 
causes of genital warts and cervical cancer were used to 
assess the knowledge of those aware of the diseases and 
HPV vaccine (i.e. knowledge index score). The third sec-
tion presented facts about HPV and contained the pay-
ment card used to assess mothers’ WTP for HPV vaccine.
Vaccine rejection was measured based on the response 
to the following question: “If the vaccine is not free, 
and you have to pay ‘out of pocket’ by yourself, will you 
vaccinate your daughter against HPV”? The follow-up 
question was used to assess willingness to pay (WTP) 
of “vaccine acceptors”. The question reads as follows: 
“If so, from the scale below mark ‘x’ on the maximum 
amount you will pay (in Naira) to have your daughter 
vaccinated against HPV”. The parents who answered 
“no” or indicated zero in the payment card were classi-
fied as “vaccine rejecters”, while the ones who answered 
“yes” and indicated a positive value in the payment card 
were classified as “vaccine acceptors”. Offered WTP val-
ues in the payment card ranged from zero to more than 
12,000 Naira (equivalent to US$ 60). The maximum price 
offered reflects the Nigerian market price for the vaccine. 
The maximum amount they were willing to pay was con-
sidered as their perceived monetary benefit of the vac-
cine. This is in accordance with welfare economic theory 
which states that the benefit to an individual of a service 
or intervention is defined as the individual’s maximum 
willingness to pay for the service or intervention.
Ethical consideration
The research design and procedure were approved by the 
ethical clearance committee of Nnamdi Azikiwe Univer-
sity Teaching Hospital Nnewi, Anambra state. The study 
secured written informed consent from the respondents. 
Anonymity of participants’ data was maintained by not 
including participants’ names.
Data analysis
Responses to the willingness-to-pay (WTP) question 
were grouped into two categories: ‘vaccine acceptors’ 
versus ‘vaccine rejecters’. The response to WTP question 
served as the dependent variables in multivariate binary 
logistic regression. The explanatory or independent vari-
ables were re-categorized into the following variables:
1. Socio-economic data: place of residence (urban or 
rural); age of respondents (three dummy codes for 
31–40 years, 41–50 years, and >50 years); household 
size (three dummy codes for 4–6 persons,  7–9 per-
sons and  ≥10 persons); occupation; average house-
hold income (4 dummy codes for US$ 251–502 
versus others, US$ 503–1256, US$ 1257–2512, 
and  >US$ 2513); whether respondent is religious; 
whether respondent is a catholic; and whether 
respondent is a protestant.
2. Awareness of HPV infection: ever diagnosed of infec-
tion, ever diagnosed of genital warts, and knowledge 
of HPV infection and consequences (summarized by 
differentiating those that answered all questions on 
knowledge of HPV infection correctly from those 
that did not).
Data were initially coded and transferred to Microsoft 
Excel (Microsoft Office 2010). Further re-categorization 
of data (i.e. creation of dummy variables) was done in 
Microsoft Excel before importing the data to SPSS (Ver-
sion 20). Multivariate binary logistic regression used 
the backward conditional as enter method and was per-
formed with SPSS version 20. A two-tailed significance 
value of 0.05 was used.
Estimation of average cost per vaccinated girl
Cost per vaccinated girl (CVG) was estimated by adjust-
ing cost of HPV vaccination delivery in Tanzania to the 
Nigerian setting [13]. We adjusted the Tanzanian HPV 
delivery cost estimates by modifying cost items—social 
mobilization/information, training, procurement (except 
for vaccine cost), vaccination, cold storage, and admin-
istration/supervision—based on the difference in local 
purchasing power between Tanzanian and Nigeria. Dif-
ference in local purchasing power was computed with 
a web-based cost of living calculator [14]. In accord-
ance with recent recommendations, vaccine procure-
ment cost was modified to reflect the cost of two doses 
at $4.50 per dose instead of 3 doses at $5 as per original 
study [15]. Vaccine price of US$ 4.50 reflects the price 
being offered by Gavi for countries eligible for support, 
while vaccine price of U$ 13 represents the lowest pub-
lic sector price offered by HPV vaccine manufactur-
ers [4]. Except for the vaccine cost, all other costs were 
inflated from 2012 (i.e. the year of publication) to 2015 
US$ value. This was done by converting adjusted cost 
in US$ to naira equivalent, inflating to 2015 value using 
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the consumer price index, and then converting back to 
US$. We used exchange rates published by Central bank 
of Nigeria [16] and consumer price index published by 
World Bank [17].
Results
Characteristics of respondents and their awareness of HPV 
infection
The overall response rate was 88 %. More than half of the 
respondent (57.1 %) resided in the rural areas. The major-
ity of the mothers who participated in the survey were 
between the ages of 31 and 50  years and were mainly 
from the Ibo tribe. Thirty percent of the respondents 
completed primary school, 38.2 % completed secondary 
school, 17.2  % had tertiary education while 10.3  % had 
post tertiary education. Only 4.3  % of respondents had 
no formal education. More than half of the respondents 
(57.6  %) reported having a household monthly income 
of less than  <US$ 251. All the respondents except one 
person had a form of religious belief. One half of the 
respondents were Catholics (Table 1).
Table  2 shows details of awareness of HPV infections 
and its consequences. Very few respondents had had 
or been diagnosed with either HPV infection or genital 
warts. Also, very few mothers had heard of HPV infec-
tion (19.1  %). Among the population that were aware 
of HPV infection, only very few had good knowledge of 
HPV infection and its consequences according to our 
knowledge index score.
Willingness to pay (WTP) for HPV infection
Average WTP value
As shown in Table  3, 401 of the respondents (91.6  %) 
stated a positive WTP amount. The average WTP 
amount stated by the respondents was US$ 5.84 per dose 
while the most frequently stated amount was US$ 2.51 
per dose. Fifty percent of the respondents stated US$ 5.03 
as the amount they are willing to pay for a dose of HPV 
vaccine.
Logistic regression predicting willingness‑to‑pay for vaccine
Thirty-three of the respondents (7.5  %) rejected HPV 
vaccination of their daughters (Table 3). Logistic regres-
sion showed that mothers living in an urban area were 
1.3 times less likely to demand for HPV vaccination for 
their daughters. Also mothers that have been previously 
diagnosed of HPV infection were 18.8 times more likely 
to demand for HPV vaccination for their daughters. The 
predictive capacity of the model was 13 %.
Table 1 Socioeconomic characteristics of  respondents 
(n = 438)
a 1 US$ = 199 Nigerian Naira




















No education 19 (4.3)
Primary education 131 (30.0)
Secondary education 167 (38.2)
Tertiary education 75 (17.2)
Post tertirary education 45 (10.3)
Monthly incomea
Less than <US $251 (N50,000) 251 (57.6)
US$ 251–502 (N50,000–N100,000) 109 (25.0)
US$ 502–1256 (N100,000–N250,000) 43 (9.9)
US$ 1256–2512 (N250,000–N500,000) 16 (3.7)
>US$ 2512 (>N500,000) 17 (3.9)
Occupation
No occupation 28 (6.4)
Farming 57 (13.1)
House wife 40 (9.2)
Public servant 110 (25.3)
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Estimated average cost per vaccinated girl
Estimate of CVG was adapted from an HPV vaccine 
delivery pilot project in Tanzania and showed that if 
HPV vaccine is supplied at vaccine alliance’s (Gavi) 
price, cost per vaccinated girl (CVG) in urban and rural 
area could cost as much as US$ 18.16 and US$ 19.26 
respectively. However, CVG could be as high as US$ 
35.16 and US$ 36.26 for urban and rural areas respec-
tively, if vaccine is supplied at the lowest price which the 
vaccine manufacturers have offered the vaccine to the 
public sector. Details of estimated CVG are shown in 
Table 4.
Discussion
This study aimed to establish how much Nigerian moth-
ers are willing to pay for vaccination of their daughters 
against HPV infection. The findings showed that the 
majority of the mothers were willing to pay an average of 
US$ 11.68 to get their daughters fully vaccinated. Moth-
ers that were previously diagnosed of HPV infection were 
more likely to demand for the vaccine. Mothers that live 
in urban areas were less likely to demand for the vaccine. 
The shortfall needed to augment the cost of vaccination 
ranges from US$ 6.48 to US$ 24.58 depending on the set-
ting of vaccine delivery (rural or urban) and the unit cost 
of HPV vaccine (Gavi’s price or lowest price offered to 
public sector).
This study has useful implications for increasing uptake 
of HPV vaccine and planning HPV vaccination in Nige-
ria. Firstly, demand for HPV vaccine is quite high. A total 
of 91.6  % of mothers were willing to pay for HPV vac-
cination of their daughters. This is opposed to the fears 
of HPV vaccine rejection that is speculated on due to 
cultural and religious sensitivities towards health inter-
ventions that target prevention of a sexually transmitted 
disease [18]. For instance, it has been stated that moth-
ers may be concerned about the vaccine being a ‘license 
to premarital sex’ [18]. Other Nigerian based population 
studies have also reported high HPV vaccine acceptance. 
A study conducted among female health care workers 
in Enugu, South-Eastern Nigeria reported HPV vaccine 
acceptability rate of 91.0 % [8]. HPV vaccine acceptance 
of 74  % among female university students in northern 
Nigeria has been reported [19]. Also, 70 % accepted vac-
cination of their daughters in a cross-sectional survey of 
mothers attending the gynaecology clinic in a Nigeria 
University Teaching Hospital [10]. High acceptance and 
demand for the vaccine points to high likelihood of HPV 
vaccination programme success in Nigeria as fundamen-
tal to the success of such programme is the recipients’ 
willingness to accept the vaccine.
The high demand for HPV vaccines could be capi-
talized upon to increase utilization of the vaccines in 
Nigeria. It could be possible to achieve higher vaccine 
uptake in Nigeria without relying on the government 
to provide the vaccine. A possible solution to achieving 
higher uptake of the vaccine is through education of the 
populace about cervical cancer and HPV vaccination. For 
example, those diagnosed of HPV infection were more 
likely to demand for HPV vaccination of their daugh-
ters. This group of persons will most likely have more in-
depth knowledge of the disease and thus, explains their 
disposition towards HPV vaccine. A systematic review by 
Table 2 Awareness of  HPV infection and  consequences 
(n = 438)
Variable Frequency (%)
Diagnosed with HPV infection 33 (7.6)
Diagnosed with genital warts 31 (7.1)
Ever heard of HPV infection 83 (19.1)
Sources of HPV infection awareness
Doctor, nurse or health professional 27 (32.9)
Family or friends 11 (13.4)
Newspaper or magazine 12 (14.6)
Television 11 (13.4)
Internet 7 (8.5)
Cannot remember 7 (8.5)
Multiple sources 7 (8.5)
Ever heard of cervical cancer 122 (27.9 %)
Good awareness of HPV infection and consequences 15 (3.4 %)
Table 3 WTP amount for HPV vaccines and its predictors







Dependent: vaccine acceptance 
(=1)
b S.E b (exp)
Vaccine rejection, n = 33
Residence (urban) −1.30 0.82 0.27
Diagnosed with HPV infection 18.76 8358.68 100,000,000
Constant −2.83 1.04 21.50
Nagelkerke R2 0.13
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Kessels et  al. [20] also identified having higher vaccine-
related knowledge, having a healthcare provider as a 
source of information and maintaining positive vaccine 
attitudes as correlates of HPV vaccine uptake in teenage 
girls. While waiting for national immunization, inter-
ventions that improve understanding of, and positive 
attitudes toward HPV vaccine could be applied. Educa-
tional interventions directed to parents or to adolescents/
young adults have been shown to be moderately effective 
in increasing HPV vaccine acceptance and uptake [21]. 
Simple educational interventions such as fact sheet about 
epidemiology and morbidity associated with HPV infec-
tion or a few minutes of radio novel about cervical cancer 
case will help increase vaccine uptake in Nigeria [21].
Another solution to achieving high HPV vaccine 
uptake is to properly orient health professionals to 
inform patients and the public about HPV vaccination. 
Even if HPV vaccination is free under the national immu-
nization programme, uptake of the vaccine will basically 
depend on whether health professionals are willing to 
inform adolescent girls about HPV vaccination. Provider-
initiated model for improving health service utilization 
appears to be effective in developing countries. For exam-
ple, increase in HIV test rates have been attributed to 
the rapid scale-up of the provider-initiated testing model 
[22]. The prescriber’s ability to educate their patient 
population on HPV vaccination must be supported and 
included as part of the national strategic plan for cervical 
cancer control. Denmark achieved very high vaccination 
rates (3-dose coverage of over 80 %) through administra-
tion by general practitioners [23].
The second important finding from our study is that 
co-payment for HPV vaccination could be a viable 
option to augment the cost of vaccination in a govern-
ment funded vaccination scenario. HPV vaccination is 
a costly programme. Even at Gavi vaccine prices, HPV 
vaccination requires substantial set up costs. Unlike new 
infant vaccines, which may be added to an existing infant 
vaccine delivery system, HPV vaccination requires the 
development of a new vaccine delivery service in order 
to achieve the required doses [6]. This is particularly so 
because of: (1) micro-planning defined as planning of 
vaccination activities at local levels that take into account 
issues of accessibility, geography, population movements, 
and cultural characteristics; (2) social mobilization/
information, education and communication; (3) higher 
cold chain equipment requirements for delivery outside 
health facility; and (4) higher service delivery costs [6]. 
With health expenditure of US$ 115 per capita and con-
sidering other competing health services including nutri-
tion activities and emergency aid [24], it is important to 
consider other financing options to support HPV vacci-
nation programme in Nigeria.
The caveat to co-payment as an option of financ-
ing HPV vaccination is that it may skew the vaccination 
programme to favour only those that can afford the vac-
cine. US$ 11.68 could be catastrophic for many to afford 
in Nigeria considering that about 99 million Nigerians 
or about 58 % of the population live with less than US$ 
1.25 per day [25]. In order to ensure equity balanced pro-
gramme, HPV vaccination should be provided for free to 
the poor populace in Nigeria. As a suggestion, a practi-
cal way to achieve this is to stratify different secondary 
schools based on their school fees and offer free vacci-
nation to schools in lowest stratum in school-based vac-
cine delivery system. Poor populations e.g. rural dwellers 
could be targeted for free vaccination in outreach vaccine 
delivery systems.
The WTP value obtained in the study has to be con-
sidered in the light of bias that is associated with open-
ended elicitation formats and WTP surveys in general. 
Respondents could have been influenced by the range 
Table 4 Estimated economic costs per fully-immunized girl (US$) in a scaled-up regional school based HPV vaccination 
programme
a Vaccine procurement cost was modified to reflect the cost of two doses at US$4.5 per dose instead of three doses at US$5 as per original study
Cost items Source data (Mwanza vaccine
 project, Tanzania) [13]
Gavi vaccine price (US$ 4.5) [4] Lowest public sector 
price (US$ 13) [4]
Urban Rural Urban Rural Urban Rural
Social mobilization/IEC 0.5 0.5 0.44 0.44 0.44 0.44
Training 0.3 0.5 0.26 0.44 0.26 0.44
Procurementa 18.7 19.4 12.46 13.11 29.46 30.11
Vaccination 5.0 4.4 4.39 3.87 4.39 3.87
Cold storage 0.2 0.3 0.18 0.26 0.18 0.26
Waste management 0.0 0.0 0.0 0.0 0.0 0.0
Admin/supervision 0.5 1.3 0.44 1.14 0.44 1.14
Total 25.3 26.6 18.16 19.26 35.16 36.26
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of values chosen for the payment scale question design 
rather than their true maximum WTP values. It is also 
possible that some respondents may have stated no WTP 
value or very low WTP value especially if they feel that 
vaccination should be paid by the government. The small 
sample size of vaccine rejecters could have induced a 
systematic bias as logistic regression could overestimate 
odd ratios in studies with small to moderate sample size 
[26]. Despite these limitations, this is the first study that 
assessed mother’s WTP for HPV vaccination in Nigeria. 
The timeliness of this study makes the findings useful for 
HPV vaccination planning in Nigeria.
Conclusion
The findings showed that Nigerian mothers were will-
ing to pay an average of US$ 11.68 for HPV vaccination 
of their daughters. At Gavi vaccine price, US$ 6.48 and 
US$ 7.58 extra are needed to augment the cost of vacci-
nation in urban and rural areas respectively. At the low-
est obtainable public sector vaccine price, US$ 23.48 and 
US$ 24.58 extra are needed to augment the cost of vac-
cination in urban and rural areas respectively. Demand 
for HPV vaccine was high and this should be capitalized 
upon to increase uptake of HPV vaccine. Educating the 
populace on cervical cancer and provider-initiated vac-
cination should be promoted as these could increase 
HPV vaccine uptake. In the event of government funded 
national vaccination, co-payment could be a feasible 
strategy to ensure sustenance of vaccination. How-
ever, free vaccination should be considered for the poor 
populace in order to ensure equity sensitive vaccination 
programme.
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